The only big ticket item comming in (AFAIK) is CLDX's 011 P2 trial in MBC. The drug is an SGEN conjucated mab. Not really a big issue for SGEN (as we get just a modest royality) but more platform confirmation.
On a smaller scale, there are numerous P1s that should be hitting the press later this year. Nothing big, and no timetable, but enough to keep upward pressure.
And lastly, sales numbers. Though SGEN is about the pipeline, there is a huge short position based around the idea that 35 will not sell. I would not be surprised if the move over the last week of so is based around the fact that the drug is selling.